Neurogenetic and Muscular Disorders Research

Spinal muscular atrophy (SMA) is a hereditary neuromuscular disease caused by mutations in the SMN1 gene, which encodes a protein essential for the survival of motor neurons—the cells that carry movement signals from the spinal cord to muscles. Without adequate SMN protein, motor neurons degenerate and the neuromuscular junctions they form with muscle tissue fail, leading to progressive weakness that, in its severest forms, is fatal in early childhood. The last decade has brought genuine therapeutic breakthroughs: antisense oligonucleotides such as nusinersen redirect the cell's splicing machinery toward a backup gene, SMN2, to boost functional protein production, while gene replacement approaches deliver a working SMN1 copy directly to motor neurons. Active research is now focused on understanding why the timing of intervention matters so profoundly, how to reach motor neurons throughout the body more effectively, and whether combining molecular strategies can sustain long-term benefit in patients across the full spectrum of disease severity.

Works

44,805

Total citations

469,397

Keywords

Spinal Muscular AtrophySMN1NusinersenGene Replacement TherapyMotor NeuronSMN2